<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619654</url>
  </required_header>
  <id_info>
    <org_study_id>PanOptix Trifocal 001, Rev A</org_study_id>
    <nct_id>NCT04619654</nct_id>
  </id_info>
  <brief_title>Visual Outcomes With a Trifocal IOL in Subjects With Open-angle Glaucoma</brief_title>
  <official_title>Visual Acuity, Refractive Predictability, and Patient Reported Quality of Vision in Subjects Implanted With a Trifocal IOL With Stable Mild Open-Angle Glaucoma Undergoing Concurrent Minimally Invasive Glaucoma Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vold Vision P.L.L.C</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vold Vision P.L.L.C</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the visual outcomes of subjects undergoing cataract surgery and&#xD;
      minimally invasive glaucoma surgery with the implantation of a trifocal intraocular lens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective single arm open label descriptive case series</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Photopic Monocular Best Corrected Distance Visual Acuity (DCVA) (4 meters) logMAR</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Monocular Best Distance Corrected Intermediate Visual Acuity (DCIVA) (60 cm) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Monocular Best Distance Corrected Near Visual Acuity (DCNVA) (40 cm) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Monocular Uncorrected Distance Visual Acuity (UCDVA) (4 meters) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Monocular Uncorrected Intermediate Visual Acuity (UCIVA) (60 cm) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Monocular Uncorrected Near Visual Acuity (UCNVA) (40 cm) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Binocular Best Corrected Distance Visual Acuity (DCVA) (4 meters) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Binocular Best Distance Corrected Intermediate Visual Acuity (DCIVA) (60 cm) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Binocular Best Distance Corrected Near Visual Acuity (DCNVA) (40 cm) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Binocular Uncorrected Distance Visual Acuity (UCDVA) (4 meters) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Binocular Uncorrected Intermediate Visual Acuity (UCIVA) (60 cm) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Binocular Uncorrected Near Visual Acuity (UCNVA) (40 cm) logMAR</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Photopic Binocular Best Corrected Distance Low Contrast Visual Acuity (25%) (4 meters) logMar</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Mesopic Binocular Best Corrected Distance Low Contrast Visual Acuity (25%) (4 meters) logMar</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Postoperative Refractive Spherical Equivalent</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Absolute Prediction Error</measure>
    <time_frame>3 months</time_frame>
    <description>Difference from postoperative refraction from preoperative biometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Vision Questionnaire (QoV)</measure>
    <time_frame>3 months</time_frame>
    <description>Grading of dysphotopsia</description>
  </other_outcome>
  <other_outcome>
    <measure>Spectacle-Dependence questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Gauging spectacle independence postoperatively</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean preoperative IOP versus postoperative IOP</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glaucoma Mean preoperative medications versus postoperative medications</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients with an IOP of less than or equal to18 mmHg and less than or equal to15 mm Hg on no glaucoma medications postoperatively</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cataract</condition>
  <condition>IOL</condition>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Cataract Surgery with concurrent MIGS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold</intervention_name>
    <description>Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent</description>
    <arm_group_label>Cataract Surgery with concurrent MIGS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects 45 years of age or older&#xD;
&#xD;
          2. A visually significant cataract&#xD;
&#xD;
          3. Diagnosis of mild OAG&#xD;
&#xD;
               -  Vertical C/D ratio of less than or equal to 0.8&#xD;
&#xD;
               -  VF characteristics consistent with glaucoma with mean deviation not worse than&#xD;
                  -6.00 dB and without fixation threatening scotoma AND/OR with nerve abnormalities&#xD;
                  consistent with glaucoma (rim notching, rim thinning, disc hemorrhage, nerve&#xD;
                  fiber layer loss)&#xD;
&#xD;
               -  Medicated IOP 25 of less than or equal to mmHg on 1-3 medications&#xD;
&#xD;
               -  If treatment na√Øve (before glaucoma treatment) IOP between 21 and 35 mmHg&#xD;
&#xD;
          4. Glaucoma must be judged as stable by investigator based on review of subject medical&#xD;
             records&#xD;
&#xD;
               -  Stable VF at least 1 year prior to surgery&#xD;
&#xD;
               -  Stable nerve fiber layer at least 1 year prior to surgery&#xD;
&#xD;
               -  IOP stable on current medication regimen at least 3 months prior to surgery&#xD;
&#xD;
          5. Shaffer grade of greater than III in all quadrants&#xD;
&#xD;
          6. Potential of good best corrected visual acuity at distance in the investigator's&#xD;
             judgement of at least 0.1 logMAR (20/25) postoperatively&#xD;
&#xD;
          7. Able and willing to comply with follow up visits&#xD;
&#xD;
          8. Understands and signs the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous incisional glaucoma surgery or cilio-ablative surgery&#xD;
&#xD;
          2. Prior laser trabeculoplasty within 90 days of surgery&#xD;
&#xD;
          3. Pseudoexfoliative, angle closure, uveitic, congenital, traumatic, angle recession, or&#xD;
             neovascular glaucoma.&#xD;
&#xD;
          4. Moderate glaucoma with VF mean deviation between -6.00 dB and -12.00 dB&#xD;
&#xD;
          5. Severe and/or progressive glaucoma defined as&#xD;
&#xD;
               -  VF mean deviation worse than -12.00 dB&#xD;
&#xD;
               -  Consistent worsening of visual field on review of subject medical records&#xD;
&#xD;
               -  Consistent and progressive thinning of nerve fiber layer on review of subject&#xD;
                  medical records&#xD;
&#xD;
               -  Uncontrolled IOP on maximum glaucoma medications&#xD;
&#xD;
               -  Historically poor IOP control with medical therapy&#xD;
&#xD;
               -  Severe focal notching of the optic nerve rim&#xD;
&#xD;
               -  Expectation for future need of incisional glaucoma surgery&#xD;
&#xD;
          6. Ocular pathology or other medical condition which, in the investigator's judgment&#xD;
             places the subject at increased risk of complications or significant vision loss&#xD;
             during study period.&#xD;
&#xD;
          7. Ocular pathology that in the investigator's judgment may impact visual acuity&#xD;
             postoperatively, i.e. significant ocular surface disease, corneal scarring,&#xD;
             blepharitis, epiretinal membrane, macular degeneration, history of significant ocular&#xD;
             trauma with sequela, etc.&#xD;
&#xD;
          8. Pregnant or breastfeeding women&#xD;
&#xD;
          9. Prior refractive surgery e.g. LASIK, RK, PRK, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael R McFarland, OD, MS</last_name>
    <phone>479-442-8653</phone>
    <email>mmcfarland@voldvision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven D Vold, MD</last_name>
    <phone>479-442-8653</phone>
    <email>svold@voldvision.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vold Vision P.L.L.C.</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael R. M OD</last_name>
      <phone>479-442-8653</phone>
      <email>mmcfarland@voldvision.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PanOptix</keyword>
  <keyword>Trifocal IOL</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>MIGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Plan to publish results in open access peer reviewed journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

